PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
205.24 - 207.41
139.95 - 221.69
4.54M / 6.59M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.81%
Positive revenue growth while AVGO is negative. John Neff might see a notable competitive edge here.
3.64%
Positive gross profit growth while AVGO is negative. John Neff would see a clear operational edge over the competitor.
4.17%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
5.51%
Positive operating income growth while AVGO is negative. John Neff might view this as a competitive edge in operations.
9.20%
Net income growth above 1.5x AVGO's 3.47%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
10.14%
EPS growth above 1.5x AVGO's 5.88%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
9.56%
Diluted EPS growth above 1.5x AVGO's 6.25%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.21%
Share reduction while AVGO is at 0.25%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.31%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
0.08%
Maintaining or increasing dividends while AVGO cut them. John Neff might see a strong edge in shareholder returns.
10.91%
Positive OCF growth while AVGO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
21.89%
Positive FCF growth while AVGO is negative. John Neff would see a strong competitive edge in net cash generation.
75.75%
10Y revenue/share CAGR under 50% of AVGO's 713.08%. Michael Burry would suspect a lasting competitive disadvantage.
22.11%
5Y revenue/share CAGR under 50% of AVGO's 172.99%. Michael Burry would suspect a significant competitive gap or product weakness.
9.87%
3Y revenue/share CAGR under 50% of AVGO's 44.71%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
220.59%
10Y OCF/share CAGR under 50% of AVGO's 4076.10%. Michael Burry would worry about a persistent underperformance in cash creation.
63.29%
Below 50% of AVGO's 383.91%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
50.95%
3Y OCF/share CAGR under 50% of AVGO's 149.93%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
255.52%
Below 50% of AVGO's 19032.54%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
95.58%
Below 50% of AVGO's 373.85%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
57.62%
Below 50% of AVGO's 338.73%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
27.78%
Below 50% of AVGO's 1418.19%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-2.72%
Negative 5Y equity/share growth while AVGO is at 335.99%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-6.47%
Negative 3Y equity/share growth while AVGO is at 9.87%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
601.27%
Dividend/share CAGR of 601.27% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
156.24%
Below 50% of AVGO's 809.51%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
102.09%
Below 50% of AVGO's 398.43%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
-5.43%
Firm’s AR is declining while AVGO shows 1.58%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-1.88%
Inventory is declining while AVGO stands at 5.51%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
3.50%
Positive asset growth while AVGO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
6.11%
Positive BV/share change while AVGO is negative. John Neff sees a clear edge over a competitor losing equity.
-0.19%
We’re deleveraging while AVGO stands at 0.05%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-2.82%
Our R&D shrinks while AVGO invests at 7.30%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-5.00%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.